Glangle M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, enhancing glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control compared to monotherapy. Glangle M2 Tablet PR is typically prescribed when diet, exercise, and monotherapy with either agent do not achieve adequate glycemic control. It is important to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily related to Metformin, and hypoglycemia associated with Glimepiride. Caution is advised in patients with renal or hepatic impairment, and contraindications include severe renal dysfunction, metabolic acidosis, and hypersensitivity to components. Glangle M2 Tablet PR should be used under medical supervision with appropriate lifestyle modifications to optimize diabetes management and reduce the risk of long-term complications.